Spotlight
Money Desk
Obituaries
Classifieds
Families First
News
Weather
Specialists
Sports
Business
Opinion
Consumer
Health
Life
Out & About
Login
Weather
4 NC counties are under alert, including Johnston County.
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
Dow Jones Industrial Average
Nasdaq Composite
Standard & Poors 500
Gold
Crude Oil
Local Stocks
WRALTechWire 30
WRALTechWire 30
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Mink Therapeutics Inc
(NQ:
INKT
)
0.8199
+0.0099 (+1.22%)
Streaming Delayed Price
Updated: 3:30 PM EDT, Sep 3, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Price and Volume
Detailed Quote
Volume
6,251
Open
0.8000
Bid (Size)
0.8101 (3)
Ask (Size)
0.8460 (3)
Prev. Close
0.8100
Today's Range
0.7950 - 0.8200
52wk Range
0.7500 - 1.900
Shares Outstanding
N/A
Dividend Yield
N/A
Intraday
1 Week
1 Month
3 Month
1 Year
3 Year
5 Year
Top News
More News
MiNK Therapeutics to Participate in H.C. Wainwright Global Investment Conference
Today 7:30 EDT
From
MiNK Therapeutics
Via
GlobeNewswire
INKT Stock Earnings: MiNK Therapeutics Beats EPS for Q2 2024
August 13, 2024
INKT stock results show that MiNK Therapeutics beat analyst estimates for earnings per share the second quarter of 2024.
Via
InvestorPlace
Performance
YTD
-24.78%
-24.78%
1 Month
+0.86%
+0.86%
3 Month
-17.61%
-17.61%
6 Month
-16.34%
-16.34%
1 Year
-46.06%
-46.06%
More News
Read More
MiNK Reports Second Quarter 2024 Results and Business Update
August 13, 2024
From
MiNK Therapeutics
Via
GlobeNewswire
MiNK Therapeutics to Provide Corporate Update and Second Quarter 2024 Financial Report
August 01, 2024
From
MiNK Therapeutics
Via
GlobeNewswire
Earnings Outlook For MiNK Therapeutics
March 20, 2024
Via
Benzinga
MiNK Therapeutics Regains Compliance with Nasdaq Capital Market Requirement
July 31, 2024
From
MiNK Therapeutics
Via
GlobeNewswire
MiNK Therapeutics Announces Virtual Annual Shareholders Meeting
June 05, 2024
From
MiNK Therapeutics
Via
GlobeNewswire
MiNK Presents AgenT-797 Clinical Activity in Immune-Compromised Transplant Patient with Severe ARDS at ATS Annual Meeting
May 22, 2024
From
MiNK Therapeutics
Via
GlobeNewswire
INKT Stock Earnings: MiNK Therapeutics Beats EPS for Q1 2024
May 14, 2024
Via
InvestorPlace
MiNK Reports First Quarter 2024 Results
May 14, 2024
From
MiNK Therapeutics
Via
GlobeNewswire
Why MiNK Therapeutics Stock Is Up 11% Monday
May 13, 2024
Via
Benzinga
12 Health Care Stocks Moving In Monday's Pre-Market Session
May 13, 2024
Via
Benzinga
MiNK Therapeutics Announces $5.8 Million Private Placement and Appointment of Board Observer
May 13, 2024
From
MiNK Therapeutics
Via
GlobeNewswire
MiNK to Provide Corporate Update and First Quarter 2024 Financial Report
April 30, 2024
From
MiNK Therapeutics
Via
GlobeNewswire
12 Health Care Stocks Moving In Monday's Intraday Session
April 08, 2024
Via
Benzinga
MiNK Therapeutics Announces Promising Preclinical Activity of MiNK-215 Against Colorectal Cancer Liver Metastases at AACR
April 08, 2024
From
MiNK Therapeutics
Via
GlobeNewswire
Why Byrna Technologies Shares Are Trading Higher By Around 7%? Here Are Other Stocks Moving In Friday's Mid-Day Session
April 05, 2024
Via
Benzinga
12 Health Care Stocks Moving In Friday's Pre-Market Session
April 05, 2024
Via
Benzinga
INKT Stock Earnings: MiNK Therapeutics Misses EPS for Q4 2023
March 21, 2024
Via
InvestorPlace
MiNK Reports Fourth Quarter and Year-End 2023 Results
March 21, 2024
From
MiNK Therapeutics
Via
GlobeNewswire
Earnings Scheduled For March 21, 2024
March 21, 2024
Via
Benzinga
MiNK to Provide Corporate Update and Fourth Quarter & Full Year 2023 Financial Report
March 07, 2024
From
MiNK Therapeutics
Via
GlobeNewswire
MiNK Announces Preclinical Data Showcasing Activity of MiNK-215 Against Colorectal Cancer Liver Metastases at AACR 2024
March 06, 2024
From
MiNK Therapeutics
Via
GlobeNewswire
First Refractory Gastric Cancer Patient Dosed in Phase 2 Trial with Novel Combination of MiNK’s Allogeneic INKT Cell Therapy and Agenus’ Botensilimab and Balstilimab
February 14, 2024
From
MiNK Therapeutics
Via
GlobeNewswire
12 Health Care Stocks Moving In Wednesday's After-Market Session
February 07, 2024
Via
Benzinga
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.